Literature DB >> 16174749

Intrathymic administration of hematopoietic progenitor cells enhances T cell reconstitution in ZAP-70 severe combined immunodeficiency.

Oumeya Adjali1, Rita R Vicente, Christophe Ferrand, Chantal Jacquet, Cédric Mongellaz, Pierre Tiberghien, Karim Chebli, Valérie S Zimmermann, Naomi Taylor.   

Abstract

Patients with severe combined immunodeficiency (SCID) present with opportunistic infections that are almost universally fatal in infancy. The mainstay treatment for these patients is allogeneic hematopoietic stem cell (HSC) transplantation, but sustained polyclonal T cell reconstitution is too often unsatisfactory. Although transplantation is conventionally performed by i.v. administration of HSC, we hypothesized that an intrathymic strategy would be superior. Indeed, several progenitor cell populations are incapable of homing to the thymus, the major site of T cell differentiation, and it appears that there are extensive time periods during which the thymus is refractory to progenitor cell import. To test this hypothesis, nonconditioned infant ZAP-70-deficient SCID mice were intrathymically injected with WT bone marrow progenitor cells, a procedure accomplished without surgical intervention. Upon intrathymic HSC injection, there was a more rapid T cell differentiation, with mature thymocytes detected by 4 weeks after transplantation. Intrathymic injection of HSC also resulted in significantly higher numbers of peripheral T cells, increased percentages of naïve T cells, and more diverse T cell receptor repertoires. Moreover, T cell reconstitution after intrathymic transplantation was obtained after injection of 10-fold fewer donor HSC. Thus, this intrathymic transplantation approach may improve the outcome of SCID patients by enhancing T cell reconstitution.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16174749      PMCID: PMC1224628          DOI: 10.1073/pnas.0504268102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

Review 1.  A positive look at double-negative thymocytes.

Authors:  Rod Ceredig; Ton Rolink
Journal:  Nat Rev Immunol       Date:  2002-11       Impact factor: 53.106

Review 2.  Gene therapy of severe combined immunodeficiencies.

Authors:  Alain Fischer; Salima Hacein-Bey; Marina Cavazzana-Calvo
Journal:  Nat Rev Immunol       Date:  2002-08       Impact factor: 53.106

3.  Intrathymically injected hemopoietic stem cells can differentiate into all lineage cells in the thymus: differences between c-kit+ cells and c-kit < low cells.

Authors:  Z Lian; J Toki; C Yu; H Hayashi; R Yasumizu; K Sugiura; T Jin; M Inaba; H Hisha; Y Li; W Yu; H Fan; S Ikehara
Journal:  Stem Cells       Date:  1997       Impact factor: 6.277

4.  Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.

Authors:  D D Patel; M E Gooding; R E Parrott; K M Curtis; B F Haynes; R H Buckley
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

5.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

6.  In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer.

Authors:  Oumeya Adjali; Gilles Marodon; Marcos Steinberg; Cédric Mongellaz; Véronique Thomas-Vaslin; Chantal Jacquet; Naomi Taylor; David Klatzmann
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

7.  Reconstitution of lymphoid development and function in ZAP-70-deficient mice following gene transfer into bone marrow cells.

Authors:  Makoto Otsu; Marcos Steinberg; Christophe Ferrand; Peggy Merida; Cosette Rebouissou; Pierre Tiberghien; Naomi Taylor; Fabio Candotti; Nelly Noraz
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

8.  Restriction of the T-cell repertoire in tumor-infiltrating lymphocytes from nine patients with renal-cell carcinoma. Relevance of the CDR3 length analysis for the identification of in situ clonal T-cell expansions.

Authors:  I Puisieux; C Bain; Y Merrouche; P Malacher; P Kourilsky; J Even; M Favrot
Journal:  Int J Cancer       Date:  1996-04-10       Impact factor: 7.396

9.  Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Authors:  Alessandro Aiuti; Shimon Slavin; Memet Aker; Francesca Ficara; Sara Deola; Alessandra Mortellaro; Shoshana Morecki; Grazia Andolfi; Antonella Tabucchi; Filippo Carlucci; Enrico Marinello; Federica Cattaneo; Sergio Vai; Paolo Servida; Roberto Miniero; Maria Grazia Roncarolo; Claudio Bordignon
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

10.  The importation of hematogenous precursors by the thymus is a gated phenomenon in normal adult mice.

Authors:  D L Foss; E Donskoy; I Goldschneider
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

View more
  9 in total

1.  Image-guided intrathymic injection of multipotent stem cells supports lifelong T-cell immunity and facilitates targeted immunotherapy.

Authors:  Andrea Z Tuckett; Raymond H Thornton; Yusuke Shono; Odette M Smith; Emily R Levy; Fabiana M Kreines; Marcel R M van den Brink; Johannes L Zakrzewski
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

2.  Correction of T cell deficiency in ZAP-70 knock-out mice by simple intraperitoneal adoptive transfer of thymocytes.

Authors:  R Kugyelka; Z Kohl; K Olasz; L Prenek; T Berki; P Balogh; F Boldizsár
Journal:  Clin Exp Immunol       Date:  2018-03-12       Impact factor: 4.330

3.  Intrathymic adeno-associated virus gene transfer rapidly restores thymic function and long-term persistence of gene-corrected T cells.

Authors:  Marie Pouzolles; Alice Machado; Mickaël Guilbaud; Magali Irla; Sarah Gailhac; Pierre Barennes; Daniela Cesana; Andrea Calabria; Fabrizio Benedicenti; Arnauld Sergé; Indu Raman; Quan-Zhen Li; Eugenio Montini; David Klatzmann; Oumeya Adjali; Naomi Taylor; Valérie S Zimmermann
Journal:  J Allergy Clin Immunol       Date:  2019-09-09       Impact factor: 10.793

4.  Free-hand ultrasound guidance permits safe and efficient minimally invasive intrathymic injections in both young and aged mice.

Authors:  Andrea Z Tuckett; Johannes L Zakrzewski; Duan Li; Marcel R M van den Brink; Raymond H Thornton
Journal:  Ultrasound Med Biol       Date:  2015-02-17       Impact factor: 2.998

Review 5.  Molecular and cellular basis of T cell lineage commitment.

Authors:  Rita Vicente; Louise Swainson; Sophie Marty-Grès; Stéphanie C De Barros; Sandrina Kinet; Valérie S Zimmermann; Naomi Taylor
Journal:  Semin Immunol       Date:  2010-07-13       Impact factor: 11.130

6.  ZAP-70 restoration in mice by in vivo thymic electroporation.

Authors:  Magali Irla; Murielle Saade; Adrien Kissenpfennig; Lionel Franz Poulin; Lee Leserman; Patrice N Marche; Evelyne Jouvin-Marche; François Berger; Catherine Nguyen
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

7.  Intrathymic transplantation of bone marrow-derived progenitors provides long-term thymopoiesis.

Authors:  Rita Vicente; Oumeya Adjali; Chantal Jacquet; Valérie S Zimmermann; Naomi Taylor
Journal:  Blood       Date:  2009-12-29       Impact factor: 22.113

8.  Intrathymic progenitor cell transplantation across histocompatibility barriers results in the persistence of early thymic progenitors and T-cell differentiation.

Authors:  Stéphanie C de Barros; Rita Vicente; Karim Chebli; Chantal Jacquet; Valérie S Zimmermann; Naomi Taylor
Journal:  Blood       Date:  2013-01-10       Impact factor: 22.113

9.  Intrathymic injection of hematopoietic progenitor cells establishes functional T cell development in a mouse model of severe combined immunodeficiency.

Authors:  Andrea Z Tuckett; Raymond H Thornton; Richard J O'Reilly; Marcel R M van den Brink; Johannes L Zakrzewski
Journal:  J Hematol Oncol       Date:  2017-05-16       Impact factor: 17.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.